INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE is a distinguished publication dedicated to advancing the understanding of psychiatric practice and mental health issues within a medical framework. Published by SAGE PUBLICATIONS INC, this journal has been a trusted source in the field since its inception, with its archives dating back to 1973. It offers a comprehensive exploration of psychiatric research, clinical studies, and theoretical advancements that seek to bridge the gap between psychiatry and general medicine. With an impact factor reflective of its quality and relevance, categorized in the Q3 quartile in Psychiatry and Mental Health, this journal stands as a vital resource for researchers, clinicians, and students alike. Although operating on a traditional subscription model, the extensive knowledge shared within its pages contributes significantly to ongoing discussions in psychiatric and mental health education and practice. As the field continually evolves, the INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE remains committed to fostering innovative and impactful scholarship that resonates with professionals navigating the complexities of mental health in clinical contexts.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Welcome to the Journal of Behavior Therapy and Experimental Psychiatry, a distinguished publication in the field of psychological research, recognized for its commitment to advancing knowledge in behavior therapy and experimental psychiatry. Published by Pergamon-Elsevier Science Ltd in the United Kingdom, this journal plays a crucial role in disseminating innovative findings and theoretical advancements since its inception in 1970. With an impressive array of impact factors, this journal proudly holds a Q1 ranking in Arts and Humanities (miscellaneous) and Q2 rankings across Clinical Psychology, Experimental and Cognitive Psychology, and Psychiatry and Mental Health categories in 2023. The journal provides a platform for both established researchers and emerging scholars to share insights that enhance practice and inform policy in mental health. Although not an Open Access journal, it ensures broad accessibility to its content through institutional subscriptions and affiliations. By focusing on high-quality, rigorous research, the Journal of Behavior Therapy and Experimental Psychiatry continues to shape the understanding of behavioral interventions and their psychological implications, making it an indispensable resource for professionals and students alike.

COMPREHENSIVE PSYCHIATRY is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by W B SAUNDERS CO-ELSEVIER INC. With its Q1 designation in both Clinical Psychology and Psychiatry and Mental Health, this journal ranks impressively, holding the 9th position out of 311 in Clinical Psychology and the 27th position out of 567 in Psychiatry and Mental Health according to Scopus metrics. Since transitioning to Open Access in 2019, COMPREHENSIVE PSYCHIATRY has significantly increased its accessibility, enabling a broader audience of researchers, mental health professionals, and students to engage with cutting-edge research and clinical practices. The journal's scope encompasses a wide array of topics, including but not limited to evidence-based interventions, psychological evaluations, and the latest empirical studies in the field. As we continue to navigate the complexities of mental health in contemporary society, this journal serves as a vital resource for disseminating impactful findings and fostering collaborative discourse among scholars and practitioners globally.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Cognitive Neuropsychiatry is a distinguished academic journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to the intersection of cognitive neuroscience and psychiatry. With a strong commitment to advancing knowledge in these rapidly evolving fields, this journal provides a platform for high-quality, peer-reviewed research that explores cognitive processes underlying psychiatric disorders. Aiming to bridge gaps between neuroscience and clinical practice, it serves as an essential resource for researchers, professionals, and students alike. As evidenced by its performance metrics, the journal ranks in the Q2 quartile for Psychiatry and Mental Health, and Q3 for Cognitive Neuroscience, showcasing its relevance and growing impact, particularly among a competitive audience. While it does not currently offer open access options, Cognitive Neuropsychiatry remains a vital outlet for disseminating impactful findings, offering insights that shape contemporary psychiatric understanding and interventions.

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.